On July 25, 2025 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, reported that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, taking place in Berlin, Germany from October 17-21 (Press release, Agenus, JUL 25, 2025, View Source [SID1234654537]). The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balstilimab in 343 evaluable patients with refractory metastatic solid tumors across five tumor types. Three additional poster presentations will feature data from investigator-sponsored studies in cervical cancer, MSS metastatic colorectal cancer (mCRC), and non-melanoma skin cancers, underscoring the broad potential of botensilimab and balstilimab based combinations in difficult-to-treat cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details:
1. Oral Presentation Title: Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Presenting Author:
Dr. Michael Gordon; HonorHealth Research Institute-AZ, USA
Mini Oral Session:
Investigational Immunotherapy
Session Date:
Friday, October 17, 2025
Session Time:
2:00-3:00 PM CEST / 8:00-9:30 AM EDT
Location:
Hall 5.2
Abstract Number:
3220
2.
Poster Presentation Title: Efficacy and safety of balstilimab with or without zalifrelimab in recurrent cervical cancer: Results from the global phase 2 RaPiDs trial
Presenting Author: Dr. David O’Malley; The Ohio State University Comprehensive Cancer Center- OH, USA
Session Date:
Saturday, October 18, 2025
Session Time:
12:00-12:45 PM CEST / 6:00-6:45 AM EDT
Location:
Hall 25
Abstract Number:
2952
Poster Number:
1164P
3.
Presentation Title: A Phase I trial of botensilimab, balstilimab and regorafenib (BBR) in chemotherapy-resistant patients with microsatellite stable (MSS) metastatic colorectal cancer
Presenting Author:
Dr. Marwan Fakih; City of Hope- CA, USA
Session Date:
Sunday, October 19, 2025
Session Time:
12:00-12:45 PM CEST / 6:00-6:45 AM EDT
Location:
Hall 25
Abstract Number:
6197
Poster Number:
851P
4.
Presentation Title: A phase 2, open label study to evaluate the safety and clinical activity of balstilimab in patients with advanced/metastatic non-melanoma skin cancers (AGENONMELA)
Presenting Author:
Dr. Iwona Lugowska; Maria Sklodowska-Curie National Research Institute and Oncology Center – Poland
Session Date:
Monday, October 20, 2025
Session Time:
12:00-12:45 PM CEST / 6:00-6:45 AM EDT
Location:
Hall 25
Abstract Number:
7273
Poster Number:
1662P